Intuitive Surgical (ISRG) has reaffirmed its robust 2026 outlook for da Vinci procedure growth and its non-GAAP gross margin range, following a solid operational performance in the second quarter of 2026. CEO David Rosa characterized the period, stating, “Our performance in Q2 was solid,” underscoring the company’s consistent execution in a competitive market.
Q2 2026 Operational Strength
The medical device innovator reported a significant uptick in procedure volumes for the second quarter. Total procedures increased by 16%, a gain primarily driven by a 15% growth in da Vinci procedures, which remain a core revenue driver. Additionally, the company’s Ion procedures demonstrated even more substantial momentum, experiencing a 36% expansion during the quarter. These figures highlight the expanding utilization and adoption of Intuitive’s advanced robotic-assisted surgical platforms across various medical specialties.
Consistent 2026 Financial Guidance
For the full fiscal year 2026, Intuitive Surgical is maintaining its previously issued guidance, signaling confidence in its market position and future demand. The company continues to forecast da Vinci procedure growth within a range of 13.5% to 15.5%. Concurrently, management has outlined a non-GAAP gross margin range of 68% to 69%, providing investors with clear expectations regarding its operational efficiency and profitability. This steadfast outlook suggests a stable trajectory for the company’s financial performance amidst ongoing healthcare sector developments.
